Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis

Leukemia

Volumn 30, Issue 7, 2016, Pages 1542-1551

  Kong, G ^a   Chang, Y I ^a,b   Damnernsawad, A ^a   You, X ^a   Du, J ^a   Ranheim, E A ^c   Lee, W ^a   Ryu, M J ^a,d   Zhou, Y ^a   Xing, Y ^a   Chang, Q ^e   Burd, C E ^f   Zhang, J ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c UNIVERSITY OF WISCONSIN   (United States)

^d Yonsei University College of Medicine   (South Korea)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 1; CD150 ANTIGEN; CD48 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N RAS PROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN; RAS PROTEIN; STEM CELL FACTOR; UNCLASSIFIED DRUG; KRAS2 PROTEIN, MOUSE; PROTEIN P21;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ALLELE; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MARROW CELL; CELL AUTONOMOUS MANNER; CELL CYCLE; CELL FUNCTION; CELL PROLIFERATION; CHROMOSOME 6; EPIGENETICS; GENE LOCUS; GENOTYPE; HEMATOPOIETIC TISSUE; LEUKEMOGENESIS; LEUKOCYTOSIS; MEGAKARYOCYTE; MONOCYTOSIS; MOUSE; MYELOID PROGENITOR CELL; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPLEEN CELL; SPLENOMEGALY; THROMBOCYTOPENIA; UNIPARENTAL DISOMY; WILD TYPE; ANIMAL; C57BL MOUSE; CARCINOGENESIS; DEFICIENCY; KNOCKOUT MOUSE; MYELOPROLIFERATIVE DISORDERS; ONCOGENE RAS; PHYSIOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSCRIPTION INITIATION;

ANIMALS; CARCINOGENESIS; GENES, RAS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOPROLIFERATIVE DISORDERS; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84964060198     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.40     Document Type: Article

References (26)

1. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366: 643-654.
2. Quilliam LA, Rebhun JF, Castro AF. A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. Prog Nucleic Acid Res Mol Biol 2002; 71: 391-444.
3. Shannon K. The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. Curr Opin Hematol 1995; 2: 305-308.
4. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689.
5. Cohen JB, Levinson AD. A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. Nature 1988; 334: 119-124.
6. Finney RE, Bishop JM. Predisposition to neoplastic transformation caused by gene replacement of H-ras1. Science 1993; 260: 1524-1527.
7. Bremner R, Balmain A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 1990; 61: 407-417.
8. Buchmann A, Ruggeri B, Klein-Szanto AJ, Balmain A. Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. Cancer Res 1991; 51: 4097-4101.
9. Zhang Z, Wang Y, Vikis HG, Johnson L, Liu G, Li J, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet 2001; 29: 25-33.
10. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, Khan G, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 2010; 18: 63-73.
11. Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, et al. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. Cancer Discov 2013; 3: 993-1001.
12. Diaz R, Ahn D, Lopez-Barcons L, Malumbres M, Perez de Castro I, Lue J, et al. The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 2002; 62: 4514-4518.
13. Wang JY, Liu YG, Li ZY, Du J, Ryu MJ, Taylor PR, et al. Endogenous oncogenic Nras mutation leads to aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 2010; 116: 5991-6002.
14. Wang JY, Liu YG, Li ZY, Wang ZD, Tan LX, Ryu MJ, et al. Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- And cell type-dependent manner. Blood 2011; 118: 368-379.
15. Burd CE, Liu W, Huynh MV, Waqas MA, Gillahan JE, Clark KS, et al. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov 2014; 4: 1418-1429.
16. Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF, et al. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood 2009; 113: 1304-1314.
17. Zhang J, Lodish HF. Identification of K-ras as the major regulator for cytokinedependent Akt activation in erythroid progenitors in vivo. Proc Natl Acad Sci USA 2005; 102: 14605-14610.
18. Kong G, Du J, Liu Y, Meline B, Chang YI, Ranheim EA, et al. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation. J Biol Chem 2013; 288: 18219-18227.
19. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, et al. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009; 7: e59.
20. Du J, Liu Y, Meline B, Kong G, Tan LX, Lo JC, et al. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals. Leukemia 2013; 27: 754-757.
21. Kong G, Wunderlich M, Yang D, Ranheim EA, Young KH, Wang J, et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. J Clin Invest 2014; 124: 2762-2773.
22. Chan IT, Kutok JL, Williams IR, Cohen S, Kelly L, Shigematsu H, et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 2004; 113: 528-538.
23. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
24. Staffas A, Karlsson C, Persson M, Palmqvist L, Bergo MO. Wild-Type KRAS inhibits oncogenic KRAS-induced T-ALL in mice. Leukemia 2014; 29: 1032-1040.
25. Chang YI, You X, Kong G, Ranheim EA, Wang J, Du J, et al. Loss of Dnmt3a and endogenous Kras cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis. Leukemia 2015; 29: 1847-1856.
26. Boggs DR. The total marrow mass of the mouse: a simplified method of measurement. Am J Hematol 1984; 16: 277-286.